XML 45 R36.htm IDEA: XBRL DOCUMENT v3.19.3
License Agreements (Details)
€ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
EUR (€)
Dec. 31, 2018
USD ($)
[1]
License Agreements [Line Items]            
Research and development $ 39,995,000 $ 10,870,000 $ 95,172,000 $ 133,356,000    
Accrued and other current liabilities 25,307,000   $ 25,307,000     $ 17,121,000
Pfizer            
License Agreements [Line Items]            
Royalty obligation period from date of first sale     12 years      
Pfizer | Asset Contribution Agreement            
License Agreements [Line Items]            
Aggregate potential milestone payments 325,000,000          
Pfizer | Asset Contribution Agreement | Minimum            
License Agreements [Line Items]            
Aggregate potential milestone payments 30,000,000          
Pfizer | Asset Contribution Agreement | Maximum            
License Agreements [Line Items]            
Aggregate potential milestone payments 60,000,000          
Aggregate potential regulatory and development milestones 840,000,000          
Cellectis | Research Collaboration and License Agreement            
License Agreements [Line Items]            
Maximum payments required per product against selected target 185,000,000          
Research and development 5,000,000 400,000 $ 5,000,000 400,000    
Accrued and other current liabilities 5,000,000   5,000,000      
Servier | License and Collaboration Agreement            
License Agreements [Line Items]            
Research and development 1,500,000 $ 4,800,000 4,500,000 $ 7,500,000    
Accrued and other current liabilities $ 1,200,000   1,200,000      
Percentage of development costs payable by the Company 60.00%          
Percentage of development cost payable by collaboration partner 40.00%          
Servier | Regulatory Milestone | License and Collaboration Agreement            
License Agreements [Line Items]            
Aggregate potential milestone receivable $ 42,000,000   42,000,000      
Servier | Regulatory Milestone | Maximum | License and Collaboration Agreement            
License Agreements [Line Items]            
Aggregate potential milestone payments 137,500,000          
Servier | Sales Milestone | License and Collaboration Agreement            
License Agreements [Line Items]            
Aggregate potential milestone receivable 77,100,000   77,100,000   € 70.5  
Servier | Sales Milestone | Maximum | License and Collaboration Agreement            
License Agreements [Line Items]            
Aggregate potential milestone payments 78,000,000          
Development and Sales | Cellectis | Maximum | Research Collaboration and License Agreement            
License Agreements [Line Items]            
Aggregate potential milestone payments $ 2,800,000,000          
Phase 1 Clinical Trial First Patient Dose | Cellectis | Research Collaboration and License Agreement            
License Agreements [Line Items]            
Aggregate potential milestone payments     $ 5,000,000      
[1] The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.